Calypte Biomedical - Verkauf startet !
Seite 4 von 4 Neuester Beitrag: 10.02.06 18:51 | ||||
| Eröffnet am: | 19.01.06 15:26 | von: Börsenfan | Anzahl Beiträge: | 92 |
| Neuester Beitrag: | 10.02.06 18:51 | von: Biomedi | Leser gesamt: | 8.031 |
| Forum: | Hot-Stocks | Leser heute: | 10 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 | > | ||||
Grüße, ZN
Rec. Time Action Price Volume
9:35:38 AM Bid 0.18 13000
9:35:24 AM Bid 0.18 13200
9:30:32 AM Ask 0.2 23000
9:30:32 AM Ask 0.2 22100
Rec. Time Action Price Volume
9:41:26 AM Ask 0.19 129000
9:41:16 AM Ask 0.19 128400
9:41:12 AM Trade 0.19 5000
9:39:42 AM Trade 0.19 2200
9:39:42 AM Ask 0.19 129000
9:38:08 AM Trade 0.18 3400
9:37:48 AM Bid 0.18 175900
9:37:46 AM Trade 0.18 10000
9:37:46 AM Bid 0.18 115900
9:37:36 AM Ask 0.19 131200
9:37:20 AM Ask 0.19 101200
9:36:50 AM Bid 0.18 125900
9:36:50 AM Ask 0.19 100600
9:36:46 AM Trade 0.18 1000
9:36:44 AM Trade 0.18 141700
-2005 Results Include $18.2 Million Tax Benefit -
BETHLEHEM, PA – February 9, 2006 – (HealthWire) – OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced revenues of $69.4 million and $18.0 million for the year and quarter ended December 31, 2005, respectively. Full year 2005 revenues represent record revenues for the Company and a 28% increase over the $54.0 million in revenues recorded in 2004. Revenues for the quarter ended December 31, 2005 were 27% higher than those for the same period in 2004.
In the fourth quarter of 2005, the Company recorded a non-cash tax benefit of approximately $26.7 million for the recognition of a significant portion of a deferred tax asset, of which approximately $18.2 million was recorded as an income tax benefit, with the remainder recorded directly to stockholders’ equity. Including this income tax benefit, the Company reported net income of $27.4 million, or $0.59 per share on a fully-diluted basis, for the full year 2005, and net income of $20.6 million, or $0.44 per share on a fully-diluted basis, for the fourth quarter of 2005. These results compare to a net loss of $560,000, or $(0.01) per share on a fully-diluted basis, and a net loss of $245,000, or $(0.01) per share on a fully-diluted basis, for the full year and quarter ended December 31, 2004, respectively.
“We are extremely pleased with the Company’s financial results for the fourth quarter and full year 2005,” said Douglas A. Michels, President and Chief Executive Officer of OraSure Technologies. “Our performance in 2005 was driven primarily by continued increases in sales to the infectious disease, substance abuse testing, and cryosurgical systems markets. Our success this past year has positioned us for continued growth in 2006 and beyond.”
--------------------------------------------------
hier werden patente, zulassungen, kooperationen und absichtserklärungen auch mal in $ umgesetzt!
nicht so bei caly: außer versprechungen, kooperationen , zulassungen, absichtserklärungen kommt da nichts...
ab ????
| ORASURE TECH INC (RT-ECN) |
|
1.60 (14.53%)kann mir beim besten willen nicht vorstellen, dass da irgendetwas fundamental schlechtes im bush sein könnte...
Kades_Gewissen, du scheinst ja nicht lange dabei zu sein, an der Boerse...
Lass mich raten, du bist seit ein paar Monaten Aktiv und versuchst dich als Mr. IQ auszugeben muhahahaha
orasure hat aber auch einen umsatz von 69.400.000$ gemacht. das ist also gerade mal ein KUV von 6,01!!!! muhhahahaahhaa
caly hat bei einem jahresumsatz von knapp 3.000.000 und einem kurs von 0,19 immer noch eine mk von 34.378.790$ !!! macht ein KUV von wahnwitzigen 11,46 !!!
noch ein kleiner unterschied: orasure macht gewinn, genauergesagt sogar: 27.400.000$ !
caly dagegen schafft es geschätzte 10.000.000$ in 2005 zu verbrennen...
aber kannst du ja jetzt machen, aktuell 0,19 -0,20$ gestellt. also sagenhafte 11,11% bzw. 5,5% im plus.
komm junge, laß dich nicht lumpen!
bei den zulassungen und zukünftigen verkäufen kann da gar nichts mehr schiefgehen! hol dir das teil, es wird dich REICH machen...muhahhahahahahaa
wo hat du das her mit der analystenerwartung?
OraSure Technologies Earns $20.6M in 4Q
Thursday February 9, 5:48 pm ET
OraSure Technologies Posts Fourth-Quarter Profit Thanks to Tax Benefit; Shares Fall on Outlook
BETHLEHEM, Pa. (AP) -- OraSure Technologies Inc., which makes an oral HIV diagnostic test and other products, reported a fourth-quarter profit on Thursday, thanks to a substantial tax benefit recorded during the quarter.
ADVERTISEMENT
Income for the quarter was $20.6 million, or 44 cents per share, up from a loss of $245,000, or a penny per share, last year. Revenue for the quarter was $18 million, up from $14.2 million last year. During the quarter the company recorded a tax benefit of $18.2 million, or 39 cents per share.
Analysts polled by Thomson Financial, on average, expected the company to earn 5 cents per share, on $18.07 million in revenue.
For the full year, income was $27.5 million, or 59 cents per share, up from a loss of $560,000, or a penny per share, last year. Revenue for the year was $69.4 million, up from $54 million last year.
For 2006, OraSure said it expects earnings for the year to range between 13 cents and 15 cents per share, while revenue is expected to grow by 25 percent over 2005 levels, implying sales of approximately $87 million. Stock option expenses are expected to reduce earnings by 4 cents to 5 cents per share.
Analysts were expecting 2006 earnings of 22 cents a share, excluding stock options, on revenue of $87 million.
Shares of OraSure were down 56 cents or 5.1 percent, in after-hours electronic trading, from Thursday's Nasdaq closing price of $11.01.